Skip to main content
OpenTrials
Completed

NCT Number: NCT02812186

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

This is a two period cross-over study randomizing patients undergoing laparoscopic surgery into 2 different groups: group 1 in which patients receive "deep neuromuscular blockade" in the beginning portion of their laparoscopic surgery followed by a period of "moderate blockade" and, group 2 in which patients receive "moderate neuromuscular blockade" in the beginning portion of their laparoscopic surgery followed by a period of "deep blockade". The deep neuromuscular block is defined as post tetanic count of 1 to 2 and the moderate neuromuscular block is defined as 1-2 twitches. In all patients, sugammadex is used to reverse the block at the end of surgery in order to obtain optimal extubating conditions.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Neuromuscular blockade (NMB) is frequently utilized in laparoscopic procedures to improve surgical conditions by relaxing the abdominal muscles and thus facilitating insufflation with carbon dioxide to optimize surgical view. Increased airway pressures can lead to an increase in alveolar and perivascular edema, a decline in dynamic lung compliance and hypoxemia.

Several studies have investigated surgical view under deep vs. moderate neuromuscular blockade. Literature supports deep neuromuscular blockade providing better operating conditions/view by a surgeon and low airway pressures but, potentially, longer duration to extubation and worse respiratory mechanics at the end of anesthesia versus moderate neuromuscular blockade which shows worse operating conditions/view by a surgeon and worse airway pressures but possibly shorter duration to extubation and better respiratory mechanics at the end of anesthesia.

Thus, there is clearly equipoise with regard to the comparative effectiveness of deep vs medium NMB. Therefore, this study is designed to ascertain if a deep neuromuscular block will decrease the airway pressures in patients undergoing laparoscopic procedures compared to those under a moderate block. A reduction in airway pressures may lead to a decrease in the complications associated with elevated airway pressures including hypoxemia, total static lung compliance, alveolar edema, and long term morbidity. Additionally, the study aims to determine if time from administration of sugammadex to reversal is different between patients that have a moderate NMB as compared to a deep NMB.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Each participant must be willing and able to provide written informed consent for the study.
  • Each participant must be American Society of Anesthesiologists (ASA) class I, II or III.
  • Each participant must be scheduled for elective laparoscopic surgery (this includes robotic laparoscopic surgery).
  • Expected surgical duration of 60 min or longer

Exclusion criteria

  • Inability to give informed oral or written consent
  • Known or suspected neuromuscular disorders impairing neuromuscular function;
  • True allergies as defined as hypotension, bronchospasm, or anaphylaxis to muscle relaxants, anesthetics or opioids
  • A history (patient or family) of malignant hyperthermia
  • A contraindication for neostigmine administration
  • Renal insufficiency, as defined by serum creatinine levels at 2.5 fold the normal level
  • Body mass index >40 kg/m^2
  • Significant respiratory disease.
  • Planned postoperative mechanical ventilation

Treatment and study plan

Deep to Moderate NMB

Procedure

Rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a "moderate" NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade.

Moderate to Deep NMB

Procedure

Rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 ("deep" NMB) the infusion will be adjusted to maintain the patient at this level of NMB.

Rocuronium

Drug

Primary outcomes

  1. Peak Airway Pressures

    Time frame: Intra-operative, from intubation time to extubation time

    To determine if a deep NMB can lead to lower peak airway pressures in patients undergoing laparoscopic procedures when compared to a moderate NMB

Secondary outcomes

  1. Abdominal Insufflation Pressure

    Time frame: Intra-operative, from intubation time to extubation time

    To compare surgical operating condition by Abdominal Insufflation Pressure in patients undergoing laparoscopic procedures using deep NMB versus moderate NMB

  2. Surgical Rating Scale

    Time frame: Intra-operative, from intubation time to extubation time

    To compare surgical operating condition by Surgical Rating Scale (SRS) in patients undergoing laparoscopic procedures using deep NMB versus moderate NMB

    Surgical Rating Score scores are on a 1-5 scale with 1 = extremely poor conditions, 2 = poor conditions, 3 = adequate conditions, 4 = good conditions, 5= excellent conditions. Higher scores mean a better outcome.

Sponsors and collaborators

Lead sponsor

Stony Brook University

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Jun 24, 2016
Registry last updated
Apr 8, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.